{
    "info": {
        "nct_id": "NCT01334060",
        "official_title": "WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation",
        "inclusion_criteria": "* CML patients:\n\nPhiladelphia chromosome positive CML in chronic phase, in complete cytogenetic response (CCyR) but with detectable BCR-ABL transcripts and maintained the CCyR on imatinib monotherapy for a minimum of 24 months\n\nAML patients:\n\nWT1+ AML in CR or morphologic CR with incomplete blood count recovery (CRi);\n\nAll patients:\n\n* ≥ 18 years of age, written informed consent\n* Performance status of 0 or 1.\n* for vaccination groups: HLA-A0201 positive in at least one allele\n* for control groups: HLA A2 negative in both alleles\n* renal function and liver function (Creatinine <1.5 x upper limit of normal, liver function tests < 1.5 x upper limit of normal); Lymphocyte count > 1.0 x109/l; normal clotting\n* HB>100 g/l\n* Adequate venous access for repeated blood sampling according to protocol schedule.\n* If sexually active and possibly fertile, patients must agree to use appropriate contraceptive methods during the trial and for six months afterwards.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* CML patients:\n\n  * CML in accelerated phase or blast crisis or having achieved CMR at any point during imatinib therapy.\n  * Imatinib dose modification in the previous year, Imatinib interruption for more than 15 days in the previous 6 months to enrolment\n  * Prior interferon-α therapy\n  * hypocellular bone marrow (<20%)\n  * Complete molecular response (CMR)\n\nAML patients:\n\n* AML in haematological relapse or eligible for allogeneic SCT.\n* hypocellular bone marrow (<20%)\n* AML patients with the \"good-risk\" abnormalities comprised by the core binding factor leukaemias (i.e., AML with the translocation (8;21) and inversion of chromosome 16, and acute promyelocytic leukaemia with the translocation (15;17))\n\nAll patients:\n\n* Systemic steroids or other drugs with a likely effect on immune competence are forbidden during the trial. The predictable need of their use will preclude the patient from trial entry\n* Major surgery in the preceding three to four weeks from which the patient has not yet recovered.\n* Patients who are of high medical risk because of non-malignant systemic disease, as well as those with active uncontrolled infection.\n* Patients with any other condition which in the Investigator's opinion would not make the patient a good candidate for the clinical trial, such as concurrent congestive heart failure or prior history of New York Heart Association (NYHA) class III/ IV cardiac disease\n* Current malignancies at other sites, with the exception of adequately treated basal or squamous cell carcinoma of the skin. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy, have no evidence of that disease for five years and are deemed at low risk for recurrence, are eligible for the study.\n* Patients who are serologically positive for or are known to suffer from Hepatitis B, C, Syphilis or HIV. Counselling will be offered to all patients prior to testing.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* CML patients:",
            "criterions": [
                {
                    "exact_snippets": "CML patients",
                    "criterion": "chronic myeloid leukemia (CML)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Philadelphia chromosome positive CML in chronic phase, in complete cytogenetic response (CCyR) but with detectable BCR-ABL transcripts and maintained the CCyR on imatinib monotherapy for a minimum of 24 months",
            "criterions": [
                {
                    "exact_snippets": "Philadelphia chromosome positive CML",
                    "criterion": "Philadelphia chromosome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic phase",
                    "criterion": "CML phase",
                    "requirements": [
                        {
                            "requirement_type": "phase",
                            "expected_value": "chronic"
                        }
                    ]
                },
                {
                    "exact_snippets": "complete cytogenetic response (CCyR)",
                    "criterion": "cytogenetic response",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "complete"
                        }
                    ]
                },
                {
                    "exact_snippets": "detectable BCR-ABL transcripts",
                    "criterion": "BCR-ABL transcripts",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "maintained the CCyR on imatinib monotherapy for a minimum of 24 months",
                    "criterion": "CCyR maintenance on imatinib",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 24,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "AML patients:",
            "criterions": [
                {
                    "exact_snippets": "AML patients",
                    "criterion": "acute myeloid leukemia (AML)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "WT1+ AML in CR or morphologic CR with incomplete blood count recovery (CRi);",
            "criterions": [
                {
                    "exact_snippets": "WT1+ AML",
                    "criterion": "WT1+ AML",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "CR or morphologic CR with incomplete blood count recovery (CRi)",
                    "criterion": "remission status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "CR",
                                "CRi"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ≥ 18 years of age, written informed consent",
            "criterions": [
                {
                    "exact_snippets": "≥ 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "written informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Performance status of 0 or 1.",
            "criterions": [
                {
                    "exact_snippets": "Performance status of 0 or 1.",
                    "criterion": "performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* for vaccination groups: HLA-A0201 positive in at least one allele",
            "criterions": [
                {
                    "exact_snippets": "HLA-A0201 positive in at least one allele",
                    "criterion": "HLA-A0201",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* for control groups: HLA A2 negative in both alleles",
            "criterions": [
                {
                    "exact_snippets": "HLA A2 negative in both alleles",
                    "criterion": "HLA A2",
                    "requirements": [
                        {
                            "requirement_type": "allele status",
                            "expected_value": "negative in both alleles"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* renal function and liver function (Creatinine <1.5 x upper limit of normal, liver function tests < 1.5 x upper limit of normal); Lymphocyte count > 1.0 x109/l; normal clotting",
            "criterions": [
                {
                    "exact_snippets": "renal function ... Creatinine <1.5 x upper limit of normal",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "Creatinine level",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x upper limit of normal"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "liver function ... liver function tests < 1.5 x upper limit of normal",
                    "criterion": "liver function",
                    "requirements": [
                        {
                            "requirement_type": "liver function tests",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x upper limit of normal"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Lymphocyte count > 1.0 x109/l",
                    "criterion": "Lymphocyte count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.0,
                                "unit": "x109/l"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "normal clotting",
                    "criterion": "clotting",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "normal"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* HB>100 g/l",
            "criterions": [
                {
                    "exact_snippets": "HB>100 g/l",
                    "criterion": "hemoglobin level",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": {
                                "operator": ">",
                                "value": 100,
                                "unit": "g/l"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate venous access for repeated blood sampling according to protocol schedule.",
            "criterions": [
                {
                    "exact_snippets": "Adequate venous access for repeated blood sampling",
                    "criterion": "venous access",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If sexually active and possibly fertile, patients must agree to use appropriate contraceptive methods during the trial and for six months afterwards.",
            "criterions": [
                {
                    "exact_snippets": "sexually active",
                    "criterion": "sexual activity",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "possibly fertile",
                    "criterion": "fertility",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "agree to use appropriate contraceptive methods",
                    "criterion": "contraceptive use",
                    "requirements": [
                        {
                            "requirement_type": "agreement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "during the trial and for six months afterwards",
                    "criterion": "contraceptive use duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": "during the trial and for six months afterwards"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "volunteer health status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "healthy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* CML patients:",
            "criterions": [
                {
                    "exact_snippets": "CML patients",
                    "criterion": "chronic myeloid leukemia (CML)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* CML in accelerated phase or blast crisis or having achieved CMR at any point during imatinib therapy.",
            "criterions": [
                {
                    "exact_snippets": "CML in accelerated phase",
                    "criterion": "CML phase",
                    "requirements": [
                        {
                            "requirement_type": "phase",
                            "expected_value": "accelerated"
                        }
                    ]
                },
                {
                    "exact_snippets": "CML in ... blast crisis",
                    "criterion": "CML phase",
                    "requirements": [
                        {
                            "requirement_type": "phase",
                            "expected_value": "blast crisis"
                        }
                    ]
                },
                {
                    "exact_snippets": "having achieved CMR at any point during imatinib therapy",
                    "criterion": "CMR achievement during imatinib therapy",
                    "requirements": [
                        {
                            "requirement_type": "achievement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Imatinib dose modification in the previous year, Imatinib interruption for more than 15 days in the previous 6 months to enrolment",
            "criterions": [
                {
                    "exact_snippets": "Imatinib dose modification in the previous year",
                    "criterion": "Imatinib dose modification",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": "previous year"
                        }
                    ]
                },
                {
                    "exact_snippets": "Imatinib interruption for more than 15 days in the previous 6 months to enrolment",
                    "criterion": "Imatinib interruption",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 15,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": "previous 6 months to enrolment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior interferon-α therapy",
            "criterions": [
                {
                    "exact_snippets": "Prior interferon-α therapy",
                    "criterion": "interferon-α therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* hypocellular bone marrow (<20%)",
            "criterions": [
                {
                    "exact_snippets": "hypocellular bone marrow (<20%)",
                    "criterion": "bone marrow cellularity",
                    "requirements": [
                        {
                            "requirement_type": "cellularity",
                            "expected_value": {
                                "operator": "<",
                                "value": 20,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Complete molecular response (CMR)",
            "criterions": [
                {
                    "exact_snippets": "Complete molecular response (CMR)",
                    "criterion": "molecular response",
                    "requirements": [
                        {
                            "requirement_type": "completeness",
                            "expected_value": "complete"
                        }
                    ]
                }
            ]
        },
        {
            "line": "AML patients:",
            "criterions": [
                {
                    "exact_snippets": "AML patients",
                    "criterion": "acute myeloid leukemia (AML)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* AML in haematological relapse or eligible for allogeneic SCT.",
            "criterions": [
                {
                    "exact_snippets": "AML in haematological relapse",
                    "criterion": "AML",
                    "requirements": [
                        {
                            "requirement_type": "relapse status",
                            "expected_value": "haematological relapse"
                        }
                    ]
                },
                {
                    "exact_snippets": "eligible for allogeneic SCT",
                    "criterion": "allogeneic SCT eligibility",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* hypocellular bone marrow (<20%)",
            "criterions": [
                {
                    "exact_snippets": "hypocellular bone marrow (<20%)",
                    "criterion": "bone marrow cellularity",
                    "requirements": [
                        {
                            "requirement_type": "cellularity",
                            "expected_value": {
                                "operator": "<",
                                "value": 20,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* AML patients with the \"good-risk\" abnormalities comprised by the core binding factor leukaemias (i.e., AML with the translocation (8;21) and inversion of chromosome 16, and acute promyelocytic leukaemia with the translocation (15;17))",
            "criterions": [
                {
                    "exact_snippets": "AML patients",
                    "criterion": "acute myeloid leukemia (AML)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "\"good-risk\" abnormalities",
                    "criterion": "good-risk abnormalities",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "core binding factor leukaemias",
                    "criterion": "core binding factor leukemias",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "AML with the translocation (8;21)",
                    "criterion": "translocation (8;21)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "inversion of chromosome 16",
                    "criterion": "inversion of chromosome 16",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "acute promyelocytic leukaemia with the translocation (15;17)",
                    "criterion": "acute promyelocytic leukemia with translocation (15;17)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Systemic steroids or other drugs with a likely effect on immune competence are forbidden during the trial. The predictable need of their use will preclude the patient from trial entry",
            "criterions": [
                {
                    "exact_snippets": "Systemic steroids or other drugs with a likely effect on immune competence are forbidden during the trial.",
                    "criterion": "use of systemic steroids or other drugs affecting immune competence",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "The predictable need of their use will preclude the patient from trial entry",
                    "criterion": "predictable need for systemic steroids or other drugs affecting immune competence",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery in the preceding three to four weeks from which the patient has not yet recovered.",
            "criterions": [
                {
                    "exact_snippets": "Major surgery in the preceding three to four weeks",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "from which the patient has not yet recovered",
                    "criterion": "recovery from surgery",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who are of high medical risk because of non-malignant systemic disease, as well as those with active uncontrolled infection.",
            "criterions": [
                {
                    "exact_snippets": "high medical risk because of non-malignant systemic disease",
                    "criterion": "non-malignant systemic disease",
                    "requirements": [
                        {
                            "requirement_type": "risk level",
                            "expected_value": "high"
                        }
                    ]
                },
                {
                    "exact_snippets": "active uncontrolled infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with any other condition which in the Investigator's opinion would not make the patient a good candidate for the clinical trial, such as concurrent congestive heart failure or prior history of New York Heart Association (NYHA) class III/ IV cardiac disease",
            "criterions": [
                {
                    "exact_snippets": "concurrent congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "prior history of New York Heart Association (NYHA) class III/ IV cardiac disease",
                    "criterion": "NYHA class III/IV cardiac disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current malignancies at other sites, with the exception of adequately treated basal or squamous cell carcinoma of the skin. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy, have no evidence of that disease for five years and are deemed at low risk for recurrence, are eligible for the study.",
            "criterions": [
                {
                    "exact_snippets": "Current malignancies at other sites",
                    "criterion": "current malignancies at other sites",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "adequately treated basal or squamous cell carcinoma of the skin",
                    "criterion": "basal or squamous cell carcinoma of the skin",
                    "requirements": [
                        {
                            "requirement_type": "treatment adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Cancer survivors, who have undergone potentially curative therapy for a prior malignancy",
                    "criterion": "prior malignancy",
                    "requirements": [
                        {
                            "requirement_type": "curative therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "no evidence of that disease for five years",
                    "criterion": "evidence of prior malignancy",
                    "requirements": [
                        {
                            "requirement_type": "absence duration",
                            "expected_value": {
                                "operator": "=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "deemed at low risk for recurrence",
                    "criterion": "risk for recurrence",
                    "requirements": [
                        {
                            "requirement_type": "risk level",
                            "expected_value": "low"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "All patients:",
            "criterions": []
        }
    ],
    "failed_exclusion": [
        {
            "line": "All patients:",
            "criterions": []
        },
        {
            "line": "* Patients who are serologically positive for or are known to suffer from Hepatitis B, C, Syphilis or HIV. Counselling will be offered to all patients prior to testing.",
            "criterions": [
                {
                    "exact_snippets": "serologically positive for ... Hepatitis B",
                    "criterion": "Hepatitis B",
                    "requirements": [
                        {
                            "requirement_type": "serological status",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "serologically positive for ... Hepatitis C",
                    "criterion": "Hepatitis C",
                    "requirements": [
                        {
                            "requirement_type": "serological status",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "serologically positive for ... Syphilis",
                    "criterion": "Syphilis",
                    "requirements": [
                        {
                            "requirement_type": "serological status",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "serologically positive for ... HIV",
                    "criterion": "HIV",
                    "requirements": [
                        {
                            "requirement_type": "serological status",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "known to suffer from ... Hepatitis B",
                    "criterion": "Hepatitis B",
                    "requirements": [
                        {
                            "requirement_type": "known condition",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known to suffer from ... Hepatitis C",
                    "criterion": "Hepatitis C",
                    "requirements": [
                        {
                            "requirement_type": "known condition",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known to suffer from ... Syphilis",
                    "criterion": "Syphilis",
                    "requirements": [
                        {
                            "requirement_type": "known condition",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known to suffer from ... HIV",
                    "criterion": "HIV",
                    "requirements": [
                        {
                            "requirement_type": "known condition",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}